Physician profile
Mark A Wigger
NPI 1306884150
$751.97
in general payments reported to CMS, 2019-2025
9 companies · $65.41 in 2025
The $65.41 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.55 · 2021: $12.91 · 2022: $113 · 2023: $165 · 2024: $383 · 2025: $65.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $465.12 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Alnylam Pharmaceuticals INC. | $108.77 | 2024 | Onpattro |
| Inspire Medical Systems, INC. | $39.90 | 2024 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.40 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $26.01 | 2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.26 | 2023 | Lifevest |
| Scpharmaceuticals INC. | $20.83 | 2023 | |
| Boston Scientific Corporation | $16.13 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wigger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.